Literature DB >> 2347148

Triple osteotomy of the pelvis. A review of 51 cases.

M A Kooijman1, P W Pavlov.   

Abstract

From 1980 to 1987, 43 patients (51 hips) were treated by triple pelvic (ischium, ilium, and pubis) osteotomy for moderate to severe symptomatic acetabular dysplasia. They were followed postoperatively for an average of 48 months (range, 18 to 84 months). In 41 patients (43 hips; 96%) there was dramatic relief of pain. The mean center-edge angle improved from 13.4 degrees to 36.1 degrees. The coverage of the femoral head was improved by an average of 25%. The authors conclude that triple osteotomy of the pelvis gives consistently good and predictable results with regard to pain relief and adequate femoral head coverage.

Entities:  

Mesh:

Year:  1990        PMID: 2347148

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  4 in total

1.  Can a triple pelvic osteotomy for adult symptomatic hip dysplasia provide relief of symptoms for 25 years?

Authors:  Renee Anne van Stralen; Gijs G van Hellemondt; Navin N Ramrattan; Enrico de Visser; Marinus de Kleuver
Journal:  Clin Orthop Relat Res       Date:  2012-11-21       Impact factor: 4.176

Review 2.  Triple pelvic osteotomy: Report of our mid-term results and review of literature.

Authors:  Tomohiro Mimura; Kanji Mori; Taku Kawasaki; Shinji Imai; Yoshitaka Matsusue
Journal:  World J Orthop       Date:  2014-01-18

3.  Gait and lower limb muscle strength in women after triple innominate osteotomy.

Authors:  Sjoerd Kolk; René Fluit; Jim Luijten; Petra J C Heesterbeek; Alexander C H Geurts; Nico Verdonschot; Vivian Weerdesteyn
Journal:  BMC Musculoskelet Disord       Date:  2015-03-24       Impact factor: 2.362

4.  Performance of Tönnis triple osteotomy in older children with developmental dysplasia of the hip (DDH) assisted by a 3D printing navigation template.

Authors:  Fei Liu; Kai Tang; Peng-Fei Zheng; Zhi-Qun Zhang; Gang Ling; Yue Lou
Journal:  BMC Musculoskelet Disord       Date:  2022-07-26       Impact factor: 2.562

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.